JCR PHARMACEUTICALS CO LTD has a total of 22 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 1999. It filed its patents most often in Australia, Taiwan and Singapore. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are SEATTLE CHILDREN S HOSPITAL DBA SEATTLE CHILDREN S RES INST, SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RES INSTITUTE) and KABIGEN AB.
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Agriculture |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Microorganisms | |
#3 | Therapeutic chemical compounds | |
#4 | Peptides | |
#5 | Enzymes | |
#6 | Animal care |
# | Name | Total Patents |
---|---|---|
#1 | Sonoda Hiroyuki | 11 |
#2 | Takahashi Kenichi | 10 |
#3 | Hosoda Yuki | 3 |
#4 | Maeda Kenichi | 3 |
#5 | Sato Kazutoshi | 3 |
#6 | Imagawa Kiwamu | 3 |
#7 | Watanabe Shunsuke | 3 |
#8 | Ishiwari Ayumi | 3 |
#9 | Higashiguchi Yasuna | 3 |
#10 | Minami Kotaro | 3 |
Publication | Filing date | Title |
---|---|---|
AU2017385288A1 | Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier | |
TW201829471A | Fusion protein including BDNF | |
AU2016283344A1 | Fusion protein containing BDNF | |
AU2005200040A1 | A therapeutic composition for treating abnormal splicing caused by excessive kinase induction |